In InsurTech, deals stall behind compliance reviews, multi-stakeholder approvals, and long sales cycles. Here is where your pipeline goes to die — and how to catch it before the quarter closes.
Who This Hits Hardest
This persona manages complex, multi-stakeholder buying processes and is most exposed to the ghost deal patterns specific to InsurTech. When a deal goes dark, this role bears the cost — in missed quota, in misleading forecasts, and in conversations with their own leadership about why the pipeline number was wrong.
What It Looks Like
An InsurTech platform vendor was carrying two large deals — one for $3.2M and one for $1.8M — both stuck in an actuarial review process that met quarterly. Neither deal had a scheduled re-engagement date. The $3.2M deal eventually closed after the VP of Product bypassed the actuarial bottleneck by framing the vendor as a strategic partnership rather than a tool purchase. The $1.8M deal was confirmed dead when the actuarial team revealed they had already selected a competing platform 11 weeks prior.
These are the phrases that appear most frequently in ghost deal CRM activity logs for this vertical. Beneath each one is what the signal actually means — and why it usually means the deal is in trouble.
"Our actuarial team needs to review this — they have a quarterly meeting schedule"
What it really means
Quarterly meeting schedules mean the next evaluation window is weeks away at minimum and months away at worst. This deal is on a forced pause until the next actuarial meeting. Do not expect any signal before then.
"We are currently evaluating multiple carriers for this — this is just one option"
What it really means
You are in a beauty contest. Beauty contests are designed to keep vendors competing without committing to any of them. Unless you have a differentiated story that makes you the obvious choice, this deal will go to whoever has the lowest price or the longest relationship.
"Our legal team needs to sign off on the data handling provisions"
What it really means
Legal sign-off is the last mile of enterprise deals — and the longest. Unless you have a contact in legal or visibility into their review process, this deal will wait indefinitely while your champion chases a signature.
InsurTech is structurally predisposed to ghost deals. The combination of long sales cycles, multi-stakeholder approval requirements, and complex internal review processes means deals can stall without any visible signal in the CRM. A deal can be in "Proposal" or "Negotiation" for 60+ days without a single person on the buying side having done anything to advance it.
The median InsurTech deal is 120 days — enough time for a champion to leave, a budget to be locked, an approval process to stall, or a competing vendor to get added to the evaluation. In most cases, none of these events are logged in the CRM. The deal just sits there, looking healthy to anyone who has not spoken to the buyer in 30 days.
What makes this especially expensive in InsurTech is the deal size. With a median ACV of $160K, each ghost deal represents significant revenue that is not in any real forecast — it is just inflating a number that will look good in the weekly pipeline review and terrible at the end of the quarter.
The three ghost phrases above are the leading indicators. But there are earlier signals worth monitoring before a deal goes fully dark: a champion who stops forwarding emails, a meeting that keeps getting rescheduled, a buyer who asks for documentation instead of a call, or a contact who starts routing you through an assistant instead of responding directly.
In InsurTech, the approval chain is often the ghost deal trigger. When a deal moves from a single champion to a multi-person approval process — compliance, legal, finance, or a committee — the deal velocity drops by 60–80% on average. A deal that was moving at one speed with one champion slows to committee speed the moment the approval process starts. If your deal has entered an approval phase and you have not established a direct contact with each approver, you are flying blind.
Budget cycles are another structural vulnerability. InsurTech companies often have fixed procurement cycles — annual, quarterly, or tied to fiscal events. A deal that misses the procurement window does not just delay; it often dies, because the budget gets reallocated and the evaluation has to restart from scratch in the next cycle. By then, your champion may have left, the business priority may have shifted, or a competitor has gotten a head start.
Revival starts with breaking through to the actual decision-maker or blocker — not just following up with the champion who has gone dark. In most cases, the champion has lost agency: they have hit the limits of their personal authority and cannot advance the deal without someone else in the organization. Emailing them more will not help.
The most effective revival tactic in InsurTech is to identify who owns the blocking decision — compliance, legal, finance, a committee, or a specific individual — and create a reason for them to engage directly. This usually means a new piece of content (a security one-pager, a legal FAQ, a ROI calculation tied to their specific business), not just another meeting request.
If the deal is truly dead — the blocker is not removable, the budget is gone, the champion has left — close it. Nothing corrupts a forecast faster than a rep who keeps a dead deal open "just in case." In InsurTech, where cycles are long and approvals are complex, the impulse to hold ghosts is even stronger than in faster-moving verticals. Push back on it. The forecast accuracy improvement from closing dead deals alone is often enough to move the number more than any single deal would have.
Run the Detector with a CSV of your deals — no sign-up required, results in 30 seconds. Or get the full forensic audit for a complete breakdown of what is stalling your pipeline and why.
No data stored. No follow-up without your consent.
Ready for a deal-by-deal breakdown? See the 14-Day Pipeline Diagnostic →